Giliad Sciences Articles
Oral PMPA Enters Phase II
10 September 1998
Battle On As Biotech Looks For New Ways Of Funding
8 September 1998
Stock Commentary New York
12 August 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
Mixed Fortunes For US Companies In 1st Qtr
14 May 1998
Gilead's Preveon Sees Success In HIV And Hep B
8 April 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Analysts Assess Outlook For US Drug Majors
8 January 1998
Gilead/Roche Begin Ph II/III GS 4104 Trials
18 December 1997
Gilead's Preveon, Expanded Access
11 December 1997
Gilead 9-Month Sales Driven By Vistide
18 November 1997
New York Stock Comment
11 September 1997
AIDS Activists Boycott Glaxo's Zantac
9 July 1997
New York Stock Comment
19 May 1997
New York Stock Comment
12 May 1997
Gilead Sciencs' Forvade Non-Approvable In USA
12 May 1997
Gilead Sciences Begins Phase I/II With Oral PMPA
12 May 1997
US Quarterly Financial Results Round-Up
5 May 1997
Phase I/II Data With Gilead's PMPA
21 April 1997
Roche And Gilead Sciences Begin Ph I With Flu Drug
17 March 1997
NEW YORK STOCK COMMENT
10 February 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
Gilead's Oral Flu Drug Nears Trials
3 February 1997
Progress With Gilead Sciences' Antivirals
3 February 1997
Gilead Sciences Begins Ph III With HIV Drug
27 January 1997
Roche's 1996 Sales Ahead Of Expectations
27 January 1997
Gilead Sciences Files NDA For Forvade
20 January 1997
Appointment At Gilead Sciences
20 January 1997
NEW YORK STOCK COMMENT
20 January 1997
Roche And Genentech In Marketing Deal
20 January 1997
Gilead's Vistide Cleared By CPMP
6 January 1997
US Quarterly Results Show Improvements
4 November 1996
Roche To Develop Gilead's Flu Drug
14 October 1996
Roche And Gilead In Hep C Copromotion
7 October 1996
Gilead Unveils Oral Flu Inhibitor GS4104
30 September 1996
European Approval of Vistide By Early 1997?
16 September 1996
New York Stock Comment
16 September 1996
P&U Gains Non-US Rights To Cidofovir
19 August 1996
Biopharmaceutical Firms Report On 2nd Qtr
12 August 1996
Gilead AIDS Treatment In Pivotal Testing
10 June 1996
Antiviral Activity Seen With Gilead's Cidofovir
3 June 1996
Gilead, GW Extend Collaboration
8 April 1996
Gilead's Cidofovir Gel For Genital warts
8 April 1996
FDA Panel Backs Gilead's Vistide For CMV Retinitis
25 March 1996
Vistide In France
18 March 1996
Chiron's Vitrasert Approved In Its First Market
11 March 1996
Vistide Review Meeting - Date Set
4 March 1996
Gilead Public Offering
26 February 1996
Gilead 4Q 1995 Results
5 February 1996
Board appointments at Gilead Sciences
15 January 1996
Gilead and Storz test Gilead nucleoside analogue drug
8 January 1996
Biotech Funding Expected To Rise On Good 1995
8 January 1996
New York Stock Comment
18 December 1995
Many US Biotech Firms See Good 3rd Qtr Sales Growth
13 November 1995
Strong Biotech Financing In 3rd Qtr
16 October 1995
Gilead Sciences: Vistide latest
16 October 1995
Gilead's Vistide: new trial data
2 October 1995
Gilead Sciences share offer
4 September 1995
Gilead Science appointment
4 September 1995
Results To June 30 See Losses For Smaller US Firms
21 August 1995
Biotech Stocks Up, But Underperforming
3 July 1995
First Results With Gilead's AIDS Treatment
8 May 1995
Expanded Access Urged For Protease Inhibitors
13 March 1995
Gilead's New Products Add To Impressive Pipeline
6 March 1995
GILEAD'S GS 504 FOR CMV RETINITIS
9 May 1994
TRIALS BEGIN ON PMEA AIDS TREATMENT
28 March 1994
INCREASE IN NEW AIDS drugs IN TRIALS IN USA FOR 1993
10 January 1994
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
8 March 1993
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
